Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Thripura Thirtala

Psychiatry Saint Peters, MO Medical Doctor

NPI 1356757116 CMS profile 487634

255 Spencer Rd Ste 201, Saint Peters, MO 63376

Open in the dashboard

General payments

$1,931

150 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Thripura Thirtala of Saint Peters, MO is reported in the CMS Open Payments database as having received $1,931 across 150 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $47 2
2022 General $46 3
2021 General $438 24
2020 General $236 16
2019 General $1,164 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thripura Thirtala
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Thripura Thirtala were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Thripura Thirtala Psychiatry median Middle half National median
2019 $1,164 $184 $59–$605 $163
2020 $236 $119 $36–$372 $114
2021 $438 $143 $43–$576 $132
2022 $46 $153 $50–$590 $149
2023 $47 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $367 21 payments
  2. Otsuka America Pharmaceutical, Inc. $267 29 payments
  3. Sunovion Pharmaceuticals Inc. $215 16 payments
  4. Janssen Pharmaceuticals, Inc $173 15 payments
  5. Allergan Inc. $135 17 payments
  6. Vanda Pharmaceuticals Inc. $120 8 payments
  7. Lundbeck LLC $113 7 payments
  8. Alkermes, Inc. $112 7 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $83 8 payments
  10. Neurocrine Biosciences, Inc. $54 4 payments
  11. Other $294 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,922 148 payments
  2. Education $8 2 payments
Products named General payments · program years 2019–2023
  1. VRAYLAR Neuroscience $367 21 payments
  2. LATUDA $215 16 payments
  3. ABILIFY MAINTENA $143 9 payments
  4. VRAYLAR Neuroscience $135 17 payments
  5. REXULTI $124 20 payments
  6. HETLIOZ $120 8 payments
  7. FANAPT $120 8 payments
  8. SPRAVATO $120 10 payments
  9. ARISTADA INITIO $112 7 payments
  10. ARISTADA $112 7 payments
  11. Other $990 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

2,832

Median for Psychiatry: 574

Drug cost

$255,226

Median for Psychiatry: $27,624

Branded share of claims

23.2%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 39 $68,801
Invega Sustenna Paliperidone Palmitate Brand 13 $44,012
Rexulti Brexpiprazole Brand 14 $27,233
Lurasidone Hcl Generic 21 $10,549
Trintellix Vortioxetine Hydrobromide Brand 15 $10,446
Vyvanse Lisdexamfetamine Dimesylate Brand 19 $7,817
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 99 $7,796
Aripiprazole Generic 112 $7,297
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 154 $5,645
Lisdexamfetamine Dimesylate Generic 20 $4,895

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$15,197

Medicare's payments for the services billed

Medicare patients

42

Average age 52

Services billed

214

23 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 50%
Depression 45%
Arthritis 29%
Heart failure 0%
Atrial fibrillation 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record